<DOC>
	<DOCNO>NCT00000649</DOCNO>
	<brief_summary>To assess safety tolerance multiple oral dos nevirapine combination zidovudine ( AZT ) ; get information pharmacokinetics ( blood level ) dose proportionality nevirapine/AZT multiple dosing ; characterize pattern virological activity vivo ( human ) nevirapine combination AZT ; determine whether development resistance either drug slow use combination . Drugs use treatment patient AIDS show toxicity limit usefulness . In addition , long-term treatment AZT , evidence virus resistance drug . Compounds effective less toxic present use would beneficial , especially active AZT-resistant virus . Nevirapine show vitro ( test tube study ) activity inhibit HIV replication ( reproduction ) . In vitro study show nevirapine AZT work together inhibit HIV replication .</brief_summary>
	<brief_title>An Open-Label , Staggered Rising Dose Cohort Study Assessing Pharmacokinetics , Safety , Tolerance BI-RG-587 Combination With Zidovudine Patients With HIV Infection ( CD4+ Cell Count &lt; 400/mm3 )</brief_title>
	<detailed_description>Drugs use treatment patient AIDS show toxicity limit usefulness . In addition , long-term treatment AZT , evidence virus resistance drug . Compounds effective less toxic present use would beneficial , especially active AZT-resistant virus . Nevirapine show vitro ( test tube study ) activity inhibit HIV replication ( reproduction ) . In vitro study show nevirapine AZT work together inhibit HIV replication . Groups 10 patient study three dose level . Five patient dose level less 3 month prior AZT treatment ; five patient dose level least 12 month previous AZT treatment tolerate AZT regimen 600 mg/day ( 200 mg every 8 hour ) . At least 24 patient-weeks treatment combination treatment must complete without require dose interruption next dosage level start . All 30 patient must enrol low dosage level high dosage level start . Patients begin treatment AZT . 14 day later , patient begin treatment nevirapine addition AZT . After 24 week , patient option continue long-term treatment either nevirapine standard treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Included : Pneumocystis carinii pneumonia prophylaxis ( sulfamethoxazole alone combination medication ) . Antifungal prophylaxis oral fluconazole ketoconazole . Antiviral prophylaxis maximum 1 g/day oral acyclovir . Patients must follow : HIV infection . Ability voluntarily provide write informed consent prior treatment . Willing able follow protocol requirement . Patients nonvisceral Kaposi 's sarcoma visceral Kaposi 's sarcoma require chemotherapy and/or irradiation may include . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Radiographic evidence chronic pulmonary disease . Cytomegalovirus disease . Toxoplasmosis encephalitis require suppressive therapy . Mycobacteriosis require maintenance chemotherapy . Visceral Kaposi 's sarcoma require chemotherapy and/or irradiation . Concurrent Medication : Excluded : Glucocorticoids steroid hormone ( include oral contraceptive ) . Dicumarol , warfarin , anticoagulant medication . Nitroglycerin . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol . Isoniazid . Antiepileptics ( Phenobarbital barbiturates ) . Sulfonamides . Excluded 4 hour 4 hour administration drug 2 : Antacids . Cimetidine . Carafate . Cholestyramine resin . Alcohol alcoholcontaining substance . Benzodiazepines ( diazepam , triazolam ) . Patients follow exclude : History clinically important disease ( defined disease , opinion investigator , may either put patient risk participation study disease may influence result study patient 's ability participate study ) HIV infection . Malignancy Kaposi 's sarcoma limit cutaneous basal cell carcinoma . Prior Medication : Excluded within 4 week prior administration study drug 2 : Antiretroviral ( zidovudine ( AZT ) ) , immunosuppressive , cytotoxic drug . Glucocorticoids steroid hormone ( include oral contraceptive ) . Dicumarol , warfarin , anticoagulant medication . Nitroglycerin . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol Isoniazid . Antiepileptics ( Phenobarbital barbiturates ) . Sulfonamides .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1993</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>